Navigation Links
Aon Study Finds Stability in Nationwide Liability Costs in the Long Term Health Care Sector
Date:5/12/2008

e of arbitration for claims settlement and significant improvements in quality of care, have combined to help alleviate the liability crisis."

In addition to reviewing trends nationwide, the Long Term Care 2008 General Liability and Professional Liability Actuarial Analysis reviewed 13 states in detail.

Of the profiled states, Alabama, California, Massachusetts, Ohio, Pennsylvania, Tennessee and Wisconsin showed increasing loss cost levels. Other states, including Arkansas, Florida, Indiana, New Jersey, Texas and West Virginia, exhibited stable or decreasing loss cost levels.

Liability costs dropped significantly in states that passed tort reform in the last several years. As a group, the average loss cost of these states (Florida, Georgia, Louisiana, Mississippi, Ohio, Texas and West Virginia) dropped from $7,190 in 1998 to an estimated loss cost of $1,230 in 2005. The loss cost for these states increased only slightly through 2007 to $1,270.

Further, both the frequency and severity of claims decreased in states that have passed tort reform. The number of claims per 1,000 occupied beds for this group peaked at 20.9 in 2002 and has since dropped to 12.2 in 2007. The average claim size plunged from $384,000 in 1998 to $104,000 in 2007.

High cost levels persist in Arkansas, California and Tennessee, where loss costs per occupied bed are multiples of countrywide averages. At $5,460, Arkansas has the highest loss cost of any state. Tennessee has the second highest loss cost at $4,510 and California the third at $3,410. The driving factor for the high loss costs in these states is average severities that are well above the national average. At the top of the list is Tennessee, with a 2007 indicated average severity of $455,000.

In all other states, excluding the thirteen states profiled, the study found that loss costs peaked in 2002 and have increased slightly since 2005. The analysis of claims in all other states indicates that
'/>"/>

SOURCE Aon Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine news :

1. Study: Kids think eyeglasses make other kids look smart
2. Homeless youth need more than treatment for substance abuse, study says
3. St. Jude study shows how T cells machinery dials down autoimmunity
4. Study Finds Nearly One-Third of All Inexpensive Earrings Examined Tested Positive for Nickel
5. Safe Options for Cardiac Lead Removal: Study Published in Heart Rhythm Journal
6. New Study Shows Lowering Co-payments Can Lead to Lower Total Healthcare Costs, Improved Overall Health
7. Study finds link between birth order and asthma symptoms
8. Study Offers Clues to Link Between Arrhythmia, Sudden Death
9. Study affirms effectiveness of medication for juvenile rheumatoid arthritis
10. Study identifies molecular response of cartilage to injury
11. Skin flaps deliver cancer-fighting therapy, ASPS study reveals
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/10/2008)...Michigan received $5 million from the National Ins...esource of high-quality experimental data sets of ...mputer-aided drug design to a new level. , The ...puter programs that can predict the effectiveness ...ciate professor in the U-M College of Pharmacy and...
(Date:10/10/2008)... Johns Hopkins University School,of Medicine is la...ptimizing Adjuvant Breast Cancer Strategies: From ...ent key research data on the latest advances in,br...ents in the treatment of breast cancer have,led to...ons that are,increasingly tailored to the specific...
(Date:10/10/2008)... The Mobile Massage Team, (http://www.mobilemassag...massage,services for corporate wellness programs, ... today that it is expanding its service area throu...lphia metropolitan region., "We are quite excited...ed, massage programs and services throughout both...
(Date:10/10/2008)...nationally recognized faculty will,present the ver...east,cancer in the multimedia course "Optimizing A...to Treatment Selection" during National Breast,Can...icing oncologists and other interested,health care...t care,advances. This accredited course offers con...
Breaking Medicine News(10 mins):Health News:U-M to house leading drug database 2Health News:Latest Research on Breast Cancer Presented in a Virtual E-Conference CME Course 2Health News:Mobile Massage Team Announces Expansion of On-Site Seated Massage Services Throughout Eastern Pennsylvania and the Greater Philadelphia Region 2Health News:Nationally Recognized Faculty Presents Latest Advances in Care of Patients with Breast Cancer 2
...n Eye Care Hospitals, one of the largest eye care ...its first branch here, with seven more in the offi...boration with K. Premraj, a prominent ophthalmic s...r of Prems' Eye Clinic. The first facility would h...
...on Americans have hypertension, that is, blood pre...n 120/80 mmHg). If untreated, it can lead to heart...anges are the first-stage treatment for the diseas...rescribed. Many patients with high blood pressure...
..., Dr Mukesh Haikerwal, today launched a unique web...//suffering fatigue, and make hospitals safer for ...Assessment website allows doctors to track their w...ng hours over a week, and determine whether their ...
...ent research published in The Lancet states that, ...y could help in faster information processing and ...emonstrated the effects of reduced levels of folat...omocysteine, in the blood of older adults which re...
Other Medicine News:Health News:Chinese Herb Shows Promise In Reducing Hypertension 2Health News:New AMA Tool Empowers Doctors to Work Safer Hours 2
(Date:10/8/2008)...ment in patients with pulmonary arterial hype...ve limited benefit for this debilitating, rap...e, -- Imatinib mesylate, available as Gleevec(R...inhibit protein associated with PAH, -- Novarti...e in PAH in 2009 EAST HANOVER, N.J., Oct. 8 ...
(Date:10/7/2008)...exas Cardiac Arrhythmia,Institute (TCAI) at St. Da...nly a few sites in the nation to participate in an...reat persistent atrial fibrillation. TCAI, an,inte...specializing in heart,rhythm disorders, is a partn...s Cardiovascular Consultants., "This is just anot...
(Date:10/7/2008)...-- CEL-SCI Corporation,(NYSE: CVM ) announced tod...reement (MTA) with the National Institutes of Heal...r. Francesco M. Marincola, M.D., to,investigate th...ironment,caused by CEL-SCI,s cancer drug Multikine...ease and Immunogentics Section, Department of Tran...
(Date:10/7/2008)...ligen Therapeutics Inc.,today announced that in vi...dates were presented at the XXII International Com...ighlighted the candidates, efficacy in,several ani...se highlighted presentations, as well as several i...l the deep expertise and expanding,knowledge base ...
Breaking Medicine Technology:Early Data Show Potential for Imatinib Mesylate Tablets to Treat Life-Threatening Form of Pulmonary Artery Disease 2Early Data Show Potential for Imatinib Mesylate Tablets to Treat Life-Threatening Form of Pulmonary Artery Disease 3Early Data Show Potential for Imatinib Mesylate Tablets to Treat Life-Threatening Form of Pulmonary Artery Disease 4Early Data Show Potential for Imatinib Mesylate Tablets to Treat Life-Threatening Form of Pulmonary Artery Disease 5Early Data Show Potential for Imatinib Mesylate Tablets to Treat Life-Threatening Form of Pulmonary Artery Disease 6Early Data Show Potential for Imatinib Mesylate Tablets to Treat Life-Threatening Form of Pulmonary Artery Disease 7Early Data Show Potential for Imatinib Mesylate Tablets to Treat Life-Threatening Form of Pulmonary Artery Disease 8Early Data Show Potential for Imatinib Mesylate Tablets to Treat Life-Threatening Form of Pulmonary Artery Disease 9Early Data Show Potential for Imatinib Mesylate Tablets to Treat Life-Threatening Form of Pulmonary Artery Disease 10Early Data Show Potential for Imatinib Mesylate Tablets to Treat Life-Threatening Form of Pulmonary Artery Disease 11Early Data Show Potential for Imatinib Mesylate Tablets to Treat Life-Threatening Form of Pulmonary Artery Disease 12Texas Cardiac Arrhythmia Institute at St. David's Medical Center Selected to Conduct Clinical Trial for Device to Treat Atrial Fibrillation 2CEL-SCI Enters Agreement With National Institutes of Health Clinical Center To Determine the Molecular Basis of Multikine Anti-Tumor Effect 2CEL-SCI Enters Agreement With National Institutes of Health Clinical Center To Determine the Molecular Basis of Multikine Anti-Tumor Effect 3In Vivo Data on Taligen Therapeutics' Pipeline Candidates Presented at the XXII International Complement Workshop 2In Vivo Data on Taligen Therapeutics' Pipeline Candidates Presented at the XXII International Complement Workshop 3In Vivo Data on Taligen Therapeutics' Pipeline Candidates Presented at the XXII International Complement Workshop 4Finding the source 3A Cells that initiate a common infant tumor identified 21225 1Brain Stem Cells Reverse Myelin Deficiency in Mice 21223 1Brain Stem Cells Reverse Myelin Deficiency in Mice 21223 2Brain Stem Cells Reverse Myelin Deficiency in Mice 21223 3Impact of Rising Gas Food Prices Felt Globally 21221 1Impact of Rising Gas Food Prices Felt Globally 21221 2Pioneering Safe Medication Return Initiative Reviewed During Pharmaceutical Disposal Summit 21219 1Pioneering Safe Medication Return Initiative Reviewed During Pharmaceutical Disposal Summit 21219 2
... ONCONASE for,Treatment of Neuroblastoma, BLOOMFIE...Alfacell Corporation today announced that new data... is active against naive and,chemoresistant neurob...vivo data published in Cancer,Letters (2007; Vol. ...ween Alfacell and Martin Michaelis, M.D., Ph.D., a...
...p; CEO of the Lupus,Foundation of America, Inc., W...- The Lupus,Foundation of America, Inc. and more t...iting the preliminary findings of the Phase,III cl...nt for,lupus kidney disease being tested by Asprev...ments for lupus patients is,critical because many ...
Other Medicine Technology:In Vitro and In Vivo Data Show Alfacell's Onocanse is Active,Against Naive and Chemoresistant Neuroblastoma Cells 2In Vitro and In Vivo Data Show Alfacell's Onocanse is Active,Against Naive and Chemoresistant Neuroblastoma Cells 3Lupus Foundation of America Statement on Results for Clinical Study,of CellCept Released by Aspreva Pharmaceutical Company 2
...s is a national reference laboratory and a worldwi...velopment. ARUP offers an extensive test menu of h... and anatomic pathology. Owned by the University o...an half of the nation's university teaching hospit...
...s is a national reference laboratory and a worldwi...velopment. ARUP offers an extensive test menu of h... and anatomic pathology. Owned by the University o...an half of the nation's university teaching hospit...
...s is a national reference laboratory and a worldwi...velopment. ARUP offers an extensive test menu of h... and anatomic pathology. Owned by the University o...an half of the nation's university teaching hospit...
...s is a national reference laboratory and a worldwi...velopment. ARUP offers an extensive test menu of h... and anatomic pathology. Owned by the University o...an half of the nation's university teaching hospit...
Medicine Products: